GlassScriptPhysician profile
Reinaldo Rosario
NPI 1043312853
$74,500.10
in general payments reported to CMS, 2019-2025
32 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,767 · 2020: $582 · 2021: $1,201 · 2022: $21K · 2023: $26K · 2024: $7,583 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $8,562 · Consulting Fee: $4,550 · Travel and Lodging: $1,603 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,775.00 |
| Food and Beverage | $8,561.56 |
| Consulting Fee | $4,550.00 |
| Travel and Lodging | $1,603.26 |
| Education | $370.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $60,614.19 | 2020-2025 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $2,148.60 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $2,027.95 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,358.91 | 2019-2025 | Krystexxa, Parsabiv, Tavneos |
| Travere Therapeutics, INC. | $1,189.74 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $932.07 | 2019-2025 | Rayaldee |
| Ani Pharmaceuticals, INC. | $655.95 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $650.45 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $629.71 | 2019-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $473.57 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $468.26 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $428.16 | 2019-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $390.46 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Akebia Therapeutics INC | $386.55 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $385.16 | 2022-2024 | Lupkynis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $221.79 | 2019-2023 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.21 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $193.07 | 2021-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $173.27 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $150.97 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $143.03 | 2022-2023 | Tremfya |
| Bard Peripheral Vascular, INC. | $138.94 | 2019 | |
| Novo Nordisk INC | $113.01 | 2025 | Ozempic |
| Mallinckrodt Enterprises LLC | $97.95 | 2019 | |
| Boston Scientific Corporation | $90.12 | 2019 | |
| Nxstage Medical, INC. | $52.52 | 2019 | |
| Kyowa Kirin, INC. | $47.12 | 2023 | Crysvita |
| Apellis Pharmaceuticals, INC. | $45.51 | 2025 | Empaveli |
| Cvrx, INC. | $33.05 | 2023 | Barostim Neo System |
| Invivyd INC | $27.45 | 2025 | Pemgarda |
| Ultragenyx Pharmaceutical INC. | $23.97 | 2023 | |
| Shield Therapeutics INC | $14.39 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reinaldo Rosario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.